Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC39, a potent and amylin-selective oral small ...

Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice The study results demonstrate ...

A once-weekly amylin analog conferred up to 10.7% weight loss at 42 weeks among adults with overweight or obesity and ...

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most ...

AbbVie will pay Gubra $350 million upfront, with up to $1.875 billion in milestone payments. GUB014295, an amylin analog for obesity, is currently in Phase 1 trials. Geopolitical tensions, Fed ...

The MAD portion of the study enrolled a total of 76 participants.

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking Therapeutics is a clinical-stage biotech that's looking to compete with Lilly in ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with or without type 2 diabetes, a pair of phase IIIa trials found. This ...

Viking Therapeutics' weight loss candidate has been looking promising. A leading drugmaker announced it's also dipping its toes into this market. However, this announcement changes little for ...

SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...